Combined fulvestrant, CDK4/6i and AKTi is needed to maintain tumor growth inhibition in breast cancer cell lines and tumor xenografts resistant to combined CDK4/6i and fulvestrant. The gene discussed is CDK4; the disease is neoplasm.